Massimo Libra - Selected Publications#

Scientific Metrics provided by Scopus:

Number of Publication: 298; Total Citions: 15627; H-index 66

1. Salemi R, Vivarelli S, Ricci D, Scillato M, Santagati M, Gattuso G, Falzone L, Libra M. Lactobacillus rhamnosus GG cell-free supernatant as a novel anti-cancer adjuvant. J Transl Med. 2023 Mar 14;21(1):195

2. Candido S, Tomasello B, Lavoro A, Falzone L, Gattuso G, Russo A, Paratore S, McCubrey JA, Libra M. Bioinformatic analysis of the LCN2-SLC22A17-MMP9 network in cancer: The role of DNA methylation in the modulation of tumor microenvironment. Front Cell Dev Biol. 2022 Sep 21;10:945586. doi: 10.3389/fcell.2022.945586. PMID: 36211450; PMCID: PMC9532607.

3. Candido S, Salemi R, Piccinin S, Falzone L, Libra M. The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways. Pharmaceutics. 2022 Mar 8;14(3):590. doi: 10.3390/pharmaceutics14030590. PMID: 35335966; PMCID: PMC8950976.

4. Vivarelli S, Falzone L, Grillo CM, Bonavida B, Crimi C, La Mantia I, Libra M. Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer. Cancers (Basel). 2022 Feb 12;14(4):922. doi: 10.3390/cancers14040922. PMID: 35205667; PMCID: PMC8869872.

5. Vivarelli S, Falzone L, Candido S, Bonavida B, Libra M. YY1 Silencing Induces 5-Fluorouracil-Resistance and <i>BCL2L15</i> Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic Relevance. Int J Mol Sci. 2021 Aug 6;22(16):8481. doi: 10.3390/ijms22168481. PMID: 34445183; PMCID: PMC8395225.

6. Vivarelli S, Candido S, Caruso G, Falzone L, Libra M. Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment. Cancers (Basel). 2020 Dec 4;12(12):3636. doi: 10.3390/cancers12123636. PMID: 33291603; PMCID: PMC7761978.

7. Falzone L, Grimaldi M, Celentano E, Augustin LSA, Libra M. Identification of Modulated MicroRNAs Associated with Breast Cancer, Diet, and Physical Activity. Cancers (Basel). 2020 Sep 8;12(9):2555. doi: 10.3390/cancers12092555. PMID: 32911851; PMCID: PMC7564431.

8. Vivarelli S, Falzone L, Ligresti G, Candido S, Garozzo A, Magro GG, Bonavida B, Libra M. Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. Int J Mol Sci. 2020 Sep 3;21(17):6446. doi: 10.3390/ijms21176446. PMID: 32899428; PMCID: PMC7504013.

9. Falzone, L., Lupo, G., La Rosa, G.R.M., Crimi, S., Anfuso, C.D., Salemi, R., Rapisarda, E., Libra, M., Candido, S. Identification of novel microRNAs and their diagnostic and prognostic significance in oral cancer. (2019) Cancers, 11 (5), art. no. 610.

10. Salemi R, Falzone L, Madonna G, Polesel J, Cinà D, Mallardo D, Ascierto PA, Libra M, Candido S.MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA. Front Pharmacol. 2018 Aug 14;9:856. doi: 10.3389/fphar.2018.00856.

11. Augustin LS, Libra M, Crispo A, Grimaldi M, De Laurentiis M, Rinaldo M, D'Aiuto M, Catalano F, Banna G, Ferrau' F, Rossello R, Serraino D, Bidoli E, Massarut S, Thomas G, Gatti D, Cavalcanti E, Pinto M, Riccardi G, Vidgen E, Kendall CW, Jenkins DJ, Ciliberto G, Montella M.Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial. BMC Cancer. 2017 Jan 23;17(1):69. doi:

Imprint Privacy policy « This page (revision-6) was last changed on Monday, 21. August 2023, 13:30 by System
  • operated by